ReviewMedicine2026
Research progress on the antitumor immune regulation mechanisms and combined treatment strategies of histotripsy: A review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histotripsy is a noninvasive, nonionizing, nonthermal ablation technology approved by the US FDA for liver cancer treatment in 2023. It exerts antitumor effects via focused ultrasound cavitation, with unique immunomodulatory advantages. Core mechanisms include inducing immunogenic cell death to form an "in situ vaccine," reshaping tumor microenvironment immune cell infiltration, regulating cytokine networks, and triggering a CD8 + T cell-mediated ferroptosis-related "abscopal effect." Combined with immune checkpoint inhibitors, antiangiogenic drugs, or chemotherapy, it shows significant synergistic efficacy. Clinical trials such as #HOPE4LIVER confirm its 95% technical success rate in hepatocellular carcinoma. With further optimization, Histotripsy is expected to benefit more solid tumor patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.